1388P Interim safety analysis of nivolumab 3mg/kg and ipilimumab 1mg/kg (nivo3/ipi1) in molecular-selected patients (pts) with metastastic castration-resistant prostate cancer (mCRPC)

Abstract

Immune checkpoint blockade (ICB) is approved for mCRPC pts with a tumor mutational burden (TMB) of > 10 mutations per megabase (mut/Mb) or mismatch repair deficiency (dMMR). More pts may benefit, particular those with DNA damage repair alterations and moderately elevated TMB. In mCRPC, nivo/ipi is more effective than monotherapy, but the applicability of nivo1/ipi3 is limited by its toxicity. This study investigates the efficacy and safety of nivo3/ipi1 in molecular-selected pts. Here, we present the results of a preplanned interim safety analysis.